Israeli pharma company, NeuroDerm Ltd., is to see data relating to its central nervous system (CNS) disease drug administration system, presented at the forthcoming American Academy of Neurology 68th Annual Meeting taking place April 15-21 in Vancouver, BC, Canada.
We’ve covered this company before, the device angle coming from the system that it employs to deliver its therapeutic agent percutaneously. Oral administration of Levodopa/Carbidopa (LD/CD) is regarded as the “gold standard” treatment for patients suffering from Parkinson’s disease. Levodopa crosses into the brain and converts into dopamine to complement the reduced brain-dopamine levels. Virtually all patients diagnosed with Parkinson’s disease will require levodopa at some point over the course of their treatment for the disease, and 70% to 80% of patients receive the drug at any given point in time. However, levodopa is limited by its short half-life. Approximately three to four hours after a single dose, almost none of the drug remains in the plasma. In addition, levodopa suffers from low absorption when administered orally, with only about 30% of the levodopa entering the blood stream.
NeuroDerm’s derivatives, ND0612H and ND0612L are designed to significantly reduce motor complications in Parkinson’s disease patients through continuous, subcutaneous delivery, maintaining steady, therapeutic levodopa plasma concentrations both day and night.
The Science Committee of the American Academy of Neurology (AAN) identified NeuroDerm’s submission for the Movement Disorders Congress, “Stable levodopa plasma levels with ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson’s disease (PD) patients with motor fluctuations,” as a critical advance in the field of neuroscience and selected the data for an encore presentation at the event next week.
Separately, pre-clinical and clinical data on the effect of continuous carbidopa on levodopa pharmacokinetics has been selected for a platform presentation.
Source: Globe Newswire